re the fool,report,of interest12 May 2015 11:00
Consumer healthcare generates about 20% of GlaxoSmithKline's (LSE: GSK) revenues, and marginally contributes to its valuation, which is more appealing than that of consumer staples such as Unilever (LSE: ULVR) and Diageo (LSE: DGE), I'd argue. Here's why.
Glaxo
Glaxo is more profitable than Unilever, with forward operating margins expected to be in mid-20s into 2016. And whilst it's less profitable than Diageo, it's financially stronger.
Revenues are unlikely to grow much, and that's not too different an outlook from that of Diageo and Unilever.
Glaxo's forward yield is forecast to hover around 5%-5.5% between 2015 and 2017 -- and such forecasts are accurate, in my view. At 21x and 11x forward earnings and adjusted operating cash flow, respectively, its stock could be considered as part of a diversified portfolio, although its earnings per share could come come under pressure this year.
The stock is up 4% so far in 2015, but has lost 12% of value over the last month, as analysts have become more bearish about its short-term earnings prospects. If you are after long-term value, there's little you should worry about at this price, however.
Finally it has long been debated whether Glaxo should hold less cyclical consumer assets, and upside could certainly come from spin-offs. Investors are nervous, though, and a change of management would benefit Glaxo's own valuation.